Abstract
Corticosteroid-induced osteoporosis, the most common and perhaps the most debilitating complication of corticosteroid therapy, is now treatable using antiresorptive bisphosphonate agents, delegates were told at the 1997 Annual Meeting of the American College of Rheumatology [Washington DC, US; November 1997]. The bisphosphonates at the centre of the breakthrough are Merck’s alendronic acid [‘Fosamax’] and Procter & Gamble’s etidronic acid [‘Didronel’]. Both have demonstrated the potential to treat corticosteroid-induced osteoporosis in large clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
